Quantcast

Latest ventricular tachycardia Stories

2009-11-09 07:30:00

NATICK, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the launch of its COGNIS® cardiac resynchronization therapy defibrillator (CRT-D) and TELIGEN® implantable cardioverter defibrillator (ICD) in Japan. These devices were approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) in August and received reimbursement approval in September. COGNIS and TELIGEN are the result of a multi-year...

2009-09-15 06:20:57

The chance that a person in cardiac arrest will survive increases when rescuers doing cardiopulmonary resuscitation (CPR) spend more time giving chest compressions, according to a multi-center study reported in Circulation: Journal of the American Heart Association. "Chest compressions move blood with oxygen to the heart and the brain to save the brain and prepare the heart to start up its own rhythm when a shock is delivered with a defibrillator," said Jim Christenson, M.D., lead author of...

2009-09-01 08:00:00

SCHAUMBURG, Ill., Sept. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of adenosine injection, USP, an antiarrhythmic drug used to treat paroxysmal supraventricular tachycardia. Sagent will offer this latex-free, preservative-free adenosine product in 6 mg per 2 mL single-dose glass vials for intravenous use. "This launch expands upon the full line of prefilled adenosine syringes we introduced in 2007,...

2009-06-02 07:15:00

LA JOLLA, Calif., June 2 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that the U.S. Food and Drug Administration (FDA) has approved the design of pivotal, Phase 2b/3 clinical trials evaluating its lead product ATPace(TM) as an antiarrhytmic drug for the acute treatment of patients with paroxysmal supraventricular tachycardia (PSVT) under the Special Protocol Assessment (SPA) process. ATPace(TM) is a novel stable liquid formulation of adenosine...

2009-05-11 06:59:32

People with a certain type of heart condition are more likely to die following coronary angioplasty or stent placement if they suffer from an irregular heart rhythm before or after the procedure. According to doctors from the Duke Clinical Research Institute, the irregular heart rhythm "“ called sustained ventricular tachycardia or fibrillation, or VT/VF "“ occurred in 5.7 percent of the 5,745 patients with ST elevation myocardial infarction (STEMI) they studied. These patients...

2009-05-08 17:37:44

Risks go up in cardiac patients having a rapid heart rhythm episode, U.S. researchers say. The study, published in the Journal of the American Medical Association, found an irregular heart rhythm known as sustained ventricular tachycardia or ventricula fibrillation, occurs in 5.7 percent of patients with an ST elevation myocardial infarction -- STEMI patients -- pattern on their electrocardiogram following a heart attack. Ninety percent of the VT/VF episodes occurred within 48 hours of...

2009-04-02 12:18:12

New research has found that the answer to treating a rare inherited heart disorder could lie with a drug already on the market. Associate Professor Derek Laver from the University of Newcastle and international colleagues have found that Flecainide "“ a drug used to treat heart arrhythmias "“ could also be used to treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CVPT is a heart arrhythmia induced by emotional stress or exercise. It is estimated to...

2009-03-04 11:38:00

LA JOLLA, Calif., March 4 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has filed a formulation patent covering its lead product, ATPace. ATPace is a stable liquid formulation of adenosine triposphate (ATP) for intravenous administration. ATPace is being developed as a therapeutic drug for the acute management of paroxysmal supraventricular tachycardia (PSVT) as well as a diagnostic test for the identification of patients with bradycardic...

2009-02-18 07:30:00

LA JOLLA, Calif., Feb. 18 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that it has submitted to the U.S. Food and Drug Administration (FDA) an amended Phase 3 protocol for ATPace to be reviewed as a Special Protocol Assessment (SPA). The amendment addresses written comments recently received from the FDA in response to the Company's initial SPA submission to the FDA on November 20, 2008. To address the FDA's main comments, Cordex has changed the...

2009-02-13 14:49:00

Conference call scheduled for Friday, February 20, at 10:00 a.m. EST LA JOLLA, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) will host a teleconference on Friday, February 20, at 10:00 a.m. EST to provide a fourth quarter business review and drug development update. Cordex's Chief Executive Officer, James S. Kuo, M.D., M.B.A., will give the presentation and there will be a question-and-answer session immediately afterwards. To participate in the...


Latest ventricular tachycardia Reference Libraries

Precordial Thump
2012-12-31 12:53:08

The precordial thump is an application of mechanical energy through a calculated strike to the torso when in a specific fatal heart rhythm. This procedure is used in very specific circumstances by highly trained health professionals with ACLS certifications. The Procedure While in the presence of a patient that is suffering a potentially fatal heart rhythm, a medical provider can strike a calculated point on the sternum to disrupt that rhythm. The energy transferred by the provider is...

More Articles (1 articles) »
Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.